Article · 2 Jun 2026
Review articlePublished 2017
Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer Therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Prostate cancer (CaP) is considered as a vexing challenge for clinical management because of its resistance to the conventional therapies, resulting in most deaths from this disease. The current treatment options including castration shows minimal effect, as most of the patients develop resistance and relapse of more aggressive Castration Resistant Prostate Cancer (CRPC). BMI1 (B cell-specific Moloney murine leukemia virus integration site 1), an oncogenic member of the polycomb group gene family and a transcriptional repressor has emerged as a key regulator in numerous processes including proliferation, differentiation, senescence, and stem cell renewal. Accumulating evidences have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in most human malignancies, including Prostate cancer. Therefore, in this review, we provide the significant evidences suggesting the potential of BMI1 as a therapeutic target in the management of prostate cancer.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Stem Cell Research & Therapy.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Stem Cell Research & Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Firdous H Beigh”
- BylineArticles whose byline prints “Nidda Syeed”
- BylineArticles whose byline prints “Mohsin Maqbool”
- BylineArticles whose byline prints “Rita Singh Majumdhar”
